A self-reported family history of pulmonary fibrosis (PF) is predictive of decreased transplant-free survival in patients with idiopathic PF (IPF) and in those with non-IPF interstitial lung disease.
Persistent inflammatory interstitial lung disease has been observed among patients following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.
Patients with pulmonary hypertension caused by interstitial lung disease experienced greater improvements in exercise capacity with inhaled treprostinil compared with placebo.
The sNDA includes data from a phase 2 trial that evaluated the efficacy and safety of pirfenidone in patients with progressive fibrosing UILD.
A high rate of mortality from COVID-19 was seen in patients with preexisting fibrotic idiopathic interstitial lung disease (ILD) compared with patients with other ILDs.
A case review demonstrates the challenges in differentiating interstitial lung disease from COVID-19 during the global pandemic.
Close monitoring of patients with systemic sclerosis-associated interstitial lung disease and awareness of the variable course of progression is highly important in considering when to initiate treatment.
ACE-1334 is a TGF-beta superfamily-based ligand trap designed to bind and inhibit TGF-beta 1 and 3 ligands.
A multidisciplinary committee of international experts have released a new clinical practice guideline on the diagnosis of adult hypersensitivity pneumonitis, an immune-mediated inflammatory lung and small airway disease.
A higher neutrophil count predicted worse disease course and higher long-term mortality in patients with systemic sclerosis-related interstitial lung disease.
